An international survey found that 77% of newly diagnosed patients with advanced NSCLC in the UK were tested for EGFR mutations and that 21% of patients for whom a test was ordered were started on first line treatment before the results were available [16]. Here, EGFR is linked to non-small cell lung carcinoma.